203 related articles for article (PubMed ID: 26178079)
1. Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.
Koh DW; Powell DP; Blake SD; Hoffman JL; Hopkins MM; Feng X
Oncol Rep; 2015 Sep; 34(3):1589-98. PubMed ID: 26178079
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the transient receptor potential melastatin-2 channel causes increased DNA damage and decreased proliferation in breast adenocarcinoma cells.
Hopkins MM; Feng X; Liu M; Parker LP; Koh DW
Int J Oncol; 2015 May; 46(5):2267-76. PubMed ID: 25760245
[TBL] [Abstract][Full Text] [Related]
3. TRPM2 channel-mediated regulation of autophagy maintains mitochondrial function and promotes gastric cancer cell survival via the JNK-signaling pathway.
Almasi S; Kennedy BE; El-Aghil M; Sterea AM; Gujar S; Partida-Sánchez S; El Hiani Y
J Biol Chem; 2018 Mar; 293(10):3637-3650. PubMed ID: 29343514
[TBL] [Abstract][Full Text] [Related]
4. TRPM2 Silencing Causes G2/M Arrest and Apoptosis in Lung Cancer Cells via Increasing Intracellular ROS and RNS Levels and Activating the JNK Pathway.
Almasi S; Long CY; Sterea A; Clements DR; Gujar S; El Hiani Y
Cell Physiol Biochem; 2019; 52(4):742-757. PubMed ID: 30933439
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor β1 induction.
Marinello PC; da Silva TN; Panis C; Neves AF; Machado KL; Borges FH; Guarnier FA; Bernardes SS; de-Freitas-Junior JC; Morgado-Díaz JA; Luiz RC; Cecchini R; Cecchini AL
Tumour Biol; 2016 Apr; 37(4):5337-46. PubMed ID: 26561471
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells.
Kulkarni YM; Yakisich JS; Azad N; Venkatadri R; Kaushik V; O'Doherty G; Iyer AKV
Tumour Biol; 2017 Jun; 39(6):1010428317705331. PubMed ID: 28618929
[TBL] [Abstract][Full Text] [Related]
7. Suppression of TRPM7 enhances TRAIL-induced apoptosis in triple-negative breast cancer cells.
Song C; Choi S; Oh KB; Sim T
J Cell Physiol; 2020 Dec; 235(12):10037-10050. PubMed ID: 32468675
[TBL] [Abstract][Full Text] [Related]
8. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
Tury S; Assayag F; Bonin F; Chateau-Joubert S; Servely JL; Vacher S; Becette V; Caly M; Rapinat A; Gentien D; de la Grange P; Schnitzler A; Lallemand F; Marangoni E; Bièche I; Callens C
J Pathol; 2018 Sep; 246(1):103-114. PubMed ID: 29876931
[TBL] [Abstract][Full Text] [Related]
9. Methods for Investigating Transient Receptor Potential Melastatin-2 (TRPM2): A Cation Channel Activated by ADP-Ribose and Involved in Cell Death.
Hall HK; Koh DW
Methods Mol Biol; 2023; 2609():213-226. PubMed ID: 36515838
[TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
Wen J; Yeo S; Wang C; Chen S; Sun S; Haas MA; Tu W; Jin F; Guan JL
Breast Cancer Res Treat; 2015 Feb; 149(3):619-29. PubMed ID: 25638397
[TBL] [Abstract][Full Text] [Related]
11. Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.
Chang LC; Hsieh MT; Yang JS; Lu CC; Tsai FJ; Tsao JW; Chiu YJ; Kuo SC; Lee KH
Int J Oncol; 2018 Jan; 52(1):67-76. PubMed ID: 29138806
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line.
Aydinlik S; Erkisa M; Cevatemre B; Sarimahmut M; Dere E; Ari F; Ulukaya E
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):49-57. PubMed ID: 27842219
[TBL] [Abstract][Full Text] [Related]
13. Transient receptor potential ion channel TRPM2 promotes AML proliferation and survival through modulation of mitochondrial function, ROS, and autophagy.
Chen SJ; Bao L; Keefer K; Shanmughapriya S; Chen L; Lee J; Wang J; Zhang XQ; Hirschler-Laszkiewicz I; Merali S; Merali C; Imamura Y; Dovat S; Madesh M; Cheung JY; Wang HG; Miller BA
Cell Death Dis; 2020 Apr; 11(4):247. PubMed ID: 32312983
[TBL] [Abstract][Full Text] [Related]
14. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines.
Pilco-Ferreto N; Calaf GM
Int J Oncol; 2016 Aug; 49(2):753-62. PubMed ID: 27278553
[TBL] [Abstract][Full Text] [Related]
15. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
Haladyna JN; Pastuer T; Riedel SS; Perraud AL; Bernt KM
Exp Hematol; 2016 Jul; 44(7):596-602.e3. PubMed ID: 27033163
[TBL] [Abstract][Full Text] [Related]
16. TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells.
Cao QF; Qian SB; Wang N; Zhang L; Wang WM; Shen HB
Cancer Biother Radiopharm; 2015 Mar; 30(2):87-93. PubMed ID: 25760728
[TBL] [Abstract][Full Text] [Related]
17. Targeting thyroid hormone receptor beta in triple-negative breast cancer.
Gu G; Gelsomino L; Covington KR; Beyer AR; Wang J; Rechoum Y; Huffman K; Carstens R; Andò S; Fuqua SA
Breast Cancer Res Treat; 2015 Apr; 150(3):535-45. PubMed ID: 25820519
[TBL] [Abstract][Full Text] [Related]
18. Role of TRPM2 and TRPV1 cation channels in cellular responses to radiation-induced DNA damage.
Masumoto K; Tsukimoto M; Kojima S
Biochim Biophys Acta; 2013 Jun; 1830(6):3382-90. PubMed ID: 23458684
[TBL] [Abstract][Full Text] [Related]
19. Transient Receptor Potential-Melastatin Channel Family Member 2: Friend or Foe.
Cheung JY; Miller BA
Trans Am Clin Climatol Assoc; 2017; 128():308-329. PubMed ID: 28790515
[TBL] [Abstract][Full Text] [Related]
20. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
